---

---

tags : Phase 2    source : Www.globenewswire.com   

save search

---

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Published: 2023-12-05 (Crawled : 12:30) - globenewswire.com
ALLR | $1.6 12.68% 600K |

n/a

| 136.71% | O: 66.69% H: 11.0% C: -42.04%
drp diagnostic cancer women companion advanced phase 2

---

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
APLM | $0.475 35K |

n/a

| -50.13% | O: 2.53% H: 0.22% C: -17.21%
ongoing trials phase 2

---

Telesat Government Solutions Awarded DARPA Space-BACN Phase 2 Contract
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
TSAT | $7.97 0.63% 0.63% 27K |

| -27.89% | O: 0.28% H: 5.81% C: 3.46%
contract solutions phase 2

---

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
SKYE | $14.1 -4.79% 73K |

Transportation and Warehousing

| 855.48% | O: 3.23% H: 6.25% C: -3.13%
sbi-100 glaucoma bioscience study phase 2

---

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ROIV | $10.95 3.3% 2.7M |

Manufacturing

| 16.1% | O: -3.29% H: 3.34% C: 3.06%
lupus results study phase 2

---

Rigetti Computing Awarded Phase 2 of DARPA Benchmarking Program
Published: 2023-11-21 (Crawled : 13:30) - globenewswire.com
RGTI | $1.175 3.98% 4.3M |

| 7.62% | O: 0.0% H: 0.0% C: -2.86%
program phase 2

---

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
Published: 2023-11-20 (Crawled : 13:30) - globenewswire.com
ATOS | $1.47 3.52% 420K |

Health Technology

| 108.82% | O: -0.34% H: 9.19% C: 9.19%
trial therapeutics phase 2

---

Akoustis Awarded Phase 2 For DARPA COFFEE Program
Published: 2023-11-16 (Crawled : 12:00) - globenewswire.com
AKTS | $0.585 7.01% 270K |

Electronic Technology

| -27.24% | O: 9.51% H: 0.27% C: -16.89%
program phase 2

---

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
IGXT | $0.1699 44K |

Manufacturing

| 35.67% | O: 7.74% H: 1.85% C: -0.96%
versafilm disease parkinson's approval montelukast trial phase 2

---

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Published: 2023-11-14 (Crawled : 06:00) - globenewswire.com
JNJ | News | $150.09 0.65% 3.9M |

Health Technology

| 1.15% | O: 0.17% H: 0.0% C: 0.0%
adx7114 study phase 2

---

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
HEPA | $1.41 41K |

Health Technology

| -51.88% | O: 2.05% H: 29.77% C: 1.34%
liver conference review pharmaceuticals trial phase 2

---

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-11-08 (Crawled : 12:30) - globenewswire.com
ATHE | $2.13 10K |

Health Technology

| -9.36% | O: 5.96% H: 8.43% C: 6.43%
ath434 system trial therapeutics phase 2

---

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
CGTX | News | $1.92 3.23% 74K |

| 75.47% | O: -2.83% H: 6.8% C: 0.97%
ct1812 disease alzheimer’s therapeutics study phase 2

---

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
Published: 2023-11-06 (Crawled : 15:00) - globenewswire.com
EVAX | $4.03 -3.82% 21K |

Manufacturing

| -63.25% | O: 5.26% H: 0.0% C: -7.5%
evx-01 phase 2

---

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
CLDX | $38.54 -0.8% 140K |

Health Technology

| 49.54% | O: 26.94% H: 1.73% C: -11.01%
urticaria positive topline therapeutics results study phase 2

---

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Published: 2023-11-05 (Crawled : 16:20) - globenewswire.com
SNY | News | $47.85 1.49% 920K |

Health Technology

| Email alert Add to watchlist
MLTX | $42.71 4.12% 220K |

| Email alert Add to watchlist
SNYNF | News | $92.7 600K |

Health Technology

| Email alert Add to watchlist
nanobody active results phase 2

---

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
OCUP | News | $1.58 4.64% 84K |

Health Technology

| -47.39% | O: 5.23% H: 2.65% C: -8.94%
apx3330 fda pharma meeting diabetic phase 2

---

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
Published: 2023-10-31 (Crawled : 15:00) - globenewswire.com
EVAX | $4.03 -3.82% 21K |

Manufacturing

| -55.19% | O: 4.81% H: 27.55% C: 14.29%
evx-01 vaccine cancer phase 2

---

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
LIFE | $1.64 170K |

Health Technology

| 31.2% | O: -0.8% H: 2.42% C: 0.81%
pharma efzofitimod study phase 2

---

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
Published: 2023-10-30 (Crawled : 13:00) - globenewswire.com
GOVX | $1.55 1.6K |

Health Technology

| 210.0% | O: 0.0% H: 2.02% C: -1.42%
covid-19 vaccine expansion trial phase 2

---

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.64 166.67% 18M |

AGBA | $2.61 108.8% 41M |

Finance

CZOO | $9.32 86.77% 18M |

EDBL | News | $6.7 78.19% 1.7M |

OPRT | News | $3.37 49.78% 8.9M |

Finance

MTC | $2.14 37.18% 4.9M |

Technology Services

VNRX | $0.8 33.33% 2.9M |

Health Technology

MLEC | $1.79 27.86% 2.6M |

n/a

PALI | $6.29 27.59% 22M |

Manufacturing

MCRB | $0.7902 26.51% 6.9M |

Health Technology

---

Your saved searches

---